<DOC>
	<DOCNO>NCT00860522</DOCNO>
	<brief_summary>This Phase 1 , open-label , dose escalation study JVRS-100 . The study proceed 2 stage minimize number patient treated dos substantially recommend phase 2 dose . In stage 1 , accelerate titration schema follow one patient dose level . Stage 2 commence dose limit toxicity observe stage 1 maximum dose stage 1 reach . Stage 2 follow modify Fibonacci schema 3-6 subject dose level recommend phase 2 dose determine . The cohort expand maximum 12 patient fully evaluate recommend phase 2 dose .</brief_summary>
	<brief_title>JVRS-100 Treatment Patients With Relapsed Refractory Leukemia</brief_title>
	<detailed_description>This Phase 1 , open-label , dose escalation study JVRS-100 . The study proceed 2 stage minimize number patient treated dos substantially recommend phase 2 dose . In stage 1 , cohort three treat dose level however dose doubled level level . Stage 2 commence dose limit toxicity observe stage 1 maximum dose stage 1 reach . Stage 2 follow modify Fibonacci schema 3-6 subject dose level recommend phase 2 dose determine . The cohort expand maximum 12 patient fully evaluate recommend phase 2 dose . The Principal Investigator assign dose level administer patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<criteria>18 year age Histologically cytologically document relapsed refractory acute leukemia Unlikely benefit standard therapy opinion investigator refuse standard therapy ECOG performance status 02 Adequate renal hepatic function No hematologic criterion WBC , Hbg platelets Negative virology screen HIV , hepatitis B surface antigen &amp; hepatitis C Female patient childbearing potential must negative serum pregnancy test Male &amp; female patient must agree use medically acceptable barrier and/or chemical contraceptive method study minimum 3 month afte last dose study treatment . Patients post blood marrow transplant demonstrate circulate CD8 count l 200 cells/ul Active CNS leukemia Current concomitant chemotherapy , radiation therapy immunotherapy Receipt investigational agent within 28 day first dose JVRS100 Persistent clinically significant toxicity prior anticancer therapy &gt; Grade 2 ( NCI CTCAE v3.0 ) Bone marrow stem cell transplant within 3 month prior first dose JVRS100 Chronic administration immunosuppressive agent within 14 day first dose JVRS100 . Use inhaled steroid , nasal spray , eye drop , topical cream small body area allow . Pregnant lactate History prior malignancy leukemia within past 5 year , exclude basal squamous cell carcinoma skin carcinoma situ cervix Patients systemic fungal , bacterial , viral , infection control Any condition , opinion investigator , would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>relapse leukemia</keyword>
	<keyword>refractory leukemia</keyword>
</DOC>